WebPHESGO is contraindicated in patients with known hypersensitivity to pertuzumab, or trastuzumab, or hyaluronidase, or to any of its excipients. Additional Important Safety … WebMar 1, 2024 · PHESGO comes in the following dosage forms: • Loading dose: Sterile solution in a 20 mL vial containing 1200 mg pertuzumab ( 80 mg/mL) and 600 mg trastuzumab (40 mg/mL). • Maintenance dose: Sterile solution in a15 mL vial containing 600 mg pertuzumab (60 mg/mL) and 600 mg trastuzumab (60 mg/mL). Do not use PHESGO if:

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION …

WebPHESGO is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer (MBC) who have not received prior … WebSep 15, 2024 · The use of pertuzumab, trastuzumab, and hyaluronidase-zzxf (Phesgo) may be considered medically when the presence of the HER2-overexpression is confirmed by the following: HER2-overexpression must be verified by ANY ONE of the following FDA approved diagnostic tests: An immunohistochemical (IHC) assay with a result of 3+ (positive); or team fat kid menu

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

WebEBC & MBC Loading dose: 1,200 mg/600 mg trastuzumab given for approx 8 min. Maintenance dose: 600 mg/600 mg trastuzumab given for approx 5 min. Patients receiving taxane Administer treatment prior to taxane. Recommended initial dose of docetaxel is 75 mg/m 2. EBC Neoadjuvant setting: 3-6 cycles depending on regimen chosen in … WebYour doctor or nurse will check for side effects during your injection and for: 30 minutes after the first injection of Phesgo. 15 minutes after subsequent injection of Phesgo. If you get any serious reaction, your doctor may stop treatment with Phesgo. Low levels of white blood cells and fever (Febrile neutropenia) WebPHESGO is a prescription medicine approved for use in combination with docetaxel in adults who have HER2-positive breast cancer that has spread to different parts of the body … eko 700 usata